Voyageur Pharmaceuticals CEO Brent Willis joins Natalie Stoberman from the Proactive studios to share the latest results from its SmoothX comparative studies.
Willis says results of the double-blind testing showed that SmoothX was favoured on drinkability and taste by 75 percent of patients compared to the competing product. Before SmoothX goes to market, Willis adds a medical white paper is currently in preparation that will provide an in-depth analysis of the studies and insights into the effectiveness of SmoothX to educate and inform doctors and medical staff about the product's benefits for abdominal CT diagnostic imaging procedures.